August 9, 2011
COLUMBUS, Ohio – Dr. David E. Cohn (43209), a physician-scientist at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), has been appointed director of the division of gynecologic oncology in the department of obstetrics and gynecology at The Ohio State University College of Medicine.
Cohn, who holds the Gertrude Parker Heer Chair in Cancer Research at OSUCCC – James, will oversee the operations of the division, and will continue to direct gynecologic cancer research and the gynecologic oncology fellowship program. He will remain the principal investigator of Ohio State's Gynecologic Oncology Group.
"In the 10 years that David has been with Ohio State, he has been an innovative surgeon and researcher, developing the latest minimally invasive robotic-assisted surgical techniques, which has made Ohio State a national leader in the field of gynecologic oncology," says Dr. Steven G. Gabbe, senior vice president for health sciences and CEO of The Ohio State University Medical Center.
Cohn, who is board-certified in gynecologic oncology, is actively involved in research for treatment and prevention of gynecologic cancers. He has extensive experience in advanced surgical techniques, including advanced robotic and laparoscopic (minimally-invasive) procedures and radical pelvic and reconstructive surgery for the diagnosis and treatment of gynecologic cancers. He has been recognized as one of "America's Top Doctors" for gynecologic cancer care.
As a member of Ohio State's Comprehensive Cancer Center, Cohn has been funded for his research into the genetics of ovarian, endometrial and cervical cancer. He serves as chair of the Clinical Science Review Committee at Ohio State's Comprehensive Cancer Center, and has been widely recognized for his excellence in teaching at Ohio State.
"David, in this new position, has the opportunity to further strengthen our already outstanding gynecologic oncology program at The James," says Dr. Michael Caligiuri, director of Ohio State's Comprehensive Cancer Center and chief executive officer of The James. As a skilled surgeon, a dedicated cancer researcher and a compassionate physician, David is uniquely qualified to advance and expand this field and build collaborations with other programs.
Cohn is a professor of obstetrics and gynecology in the division of gynecologic oncology at Ohio State, where he has been a faculty member since 2001. He completed his undergraduate work at the University of Michigan and received his medical degree from the Georgetown University School of Medicine in Washington, D.C. He completed his residency at the University of Washington Medical Center in Seattle and his fellowship in Gynecologic Oncology at Washington University School of Medicine in St. Louis.
Cohn is a member of the American Gynecological and Obstetrical Society, the Society of Gynecologic Oncologists, the American Association for Cancer Research, the American Society of Clinical Oncology and the American College of Obstetricians and Gynecologists. He serves on the editorial board for Gynecologic Oncology and numerous national committees related to gynecologic oncology.
Dr. Jeffrey Fowler (43209), former director of the division of gynecologic oncology, will be promoted to vice-chair of the department of obstetrics and gynecology at Ohio State. Fowler, who is a physician-scientist at OSUCCC – James holds the John G. Boutselis Chair of Gynecologic Oncology and co-directs Ohio State's Center for Advanced Robotic Surgery.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is one of only 41 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute and was recently awarded the highest ranking possible – exceptional – by NCI. Ranked by U.S. News & World Report among the top cancer hospitals in the nation, The James is the 210-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC – James is one of only seven centers in the country funded by the NCI to conduct both phase I and phase II clinical trials.
# # #
